prostate cancer (mCRPC)
Oncology · 2005–2025
32decisions
12medicines
12carried consumer input
194individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| abiraterone acetate and prednisolone Treatment of patients with metastatic castration resistant prostate cancer (mCRPC) who are asymptomatic or mildly symptomatic after failure of androgen… | Jul 2025 | Recommended with restriction | input received Rare Cancers Australia |
| talazoparib First-line treatment of metastatic castration-resistant prostate cancer (mCRPC) in patients with BRCA1/2 pathogenic variants who have not received prior… | Jul 2024 | Recommended | unclear |
| talazoparib First-line treatment of metastatic castration-resistant prostate cancer (mCRPC) in patients with BRCA1/2 pathogenic variants who have not received prior… | Mar 2024 | Not recommended | input received Rare Cancers Australia |
| olaparib First-line treatment of metastatic castration-resistant prostate cancer (mCRPC) in patients with BRCA1/2 pathogenic variants who have not received prior… | Nov 2023 | Not recommended | 10 individuals Medical Oncology Group · Prostate Cancer Foundation · Blue Mountains Prostate Cancer Support Group · Bega Valley Prostate Cancer Support Group · South Eastern Prostate Cancer Support Group · Prostate Cancer Support Group · Mens Cancer Support Group · Bayside Kingston Prostate Cancer Support Group · Cancer Support Group · Lakes Entrance Prostate Cancer Support Group · Grafton Prostate Cancer Support Group · Support Group |
| abiraterone acetate and methylprednisolone Treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). The co-pack comprises abiraterone acetate tablets in a fine particle… | Mar 2022 | Not recommended | none received |
| cabazitaxel Treatment of castration resistant metastatic carcinoma of the prostate in patients previously treated with a docetaxel-containing regimen, in combination with… | Mar 2022 | Recommended with restriction | none received |
| abiraterone acetate and methylprednisolone Treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) who are asymptomatic or mildly symptomatic after failure of androgen… | Nov 2022 | Recommended with restriction | input received |
| darolutamide Treatment of patients with castration resistant prostate cancer (CRPC), specifically non-metastatic CRPC (m0CRPC) with a prostate-specific antigen doubling… | Jul 2021 | Recommended with restriction | 7 individuals |
| abiraterone acetate, enzalutamide Amendment to existing listings for metastatic castration-resistant prostate cancer (mCRPC) to allow use prior to docetaxel treatment (pre-docetaxel setting),… | Mar 2021 | Recommended | no section in document |
| cabazitaxel Treatment of patients with castration resistant metastatic carcinoma of the prostate, in combination with prednisone or prednisolone, in patients who have… | Mar 2021 | Recommended with restriction | none received |
| olaparib Treatment of adult patients with BRCA-mutated (germline and/or somatic) metastatic castration-resistant prostate cancer who have progressed following prior… | Mar 2021 | Not recommended | input received Prostate Cancer Foundation |
| olaparib Treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) with BRCA1/2 pathogenic variants who have progressed following prior… | Nov 2021 | Recommended | input received |
| abiraterone acetate Treatment of metastatic castration-resistant carcinoma of the prostate in combination with a corticosteroid. | Jul 2017 | Recommended with restriction | none received |
| enzalutamide Treatment of metastatic castration-resistant prostate cancer (mCRPC) prior to docetaxel in patients who have failed or are unsuitable for androgen deprivation… | Jul 2017 | Deferred | unclear |
| abiraterone acetate Treatment of metastatic castration-resistant prostate cancer (mCRPC) in combination with corticosteroids (expanded from prednisone/prednisolone to any… | Mar 2017 | Recommended with restriction | none received |
| docetaxel Treatment of castrate-resistant metastatic prostate cancer; also indicated for other malignancies including breast cancer and non-small cell lung cancer (per… | Mar 2017 | Recommended | no section in document |
| enzalutamide Treatment of metastatic castration-resistant prostate cancer (mCRPC) in asymptomatic patients who have not yet received docetaxel. | Mar 2017 | Deferred | 90 individuals |
| radium-223 dichloride Treatment of castration resistant metastatic carcinoma of the prostate in patients with symptomatic bone metastases and no known visceral metastatic disease. | Nov 2017 | Recommended with restriction | 9 individuals Prostate Cancer Foundation · Prostate Heidelberg Cancer Supporters Group |
| enzalutamide Treatment of metastatic castration-resistant prostate cancer (mCRPC) in chemotherapy-naïve patients who have not had prior docetaxel. | Nov 2015 | Not recommended | 12 individuals |
| abiraterone acetate Treatment of metastatic castration-resistant prostate cancer (mCRPC) in chemotherapy-naïve patients who are asymptomatic or mildly symptomatic after failure of… | Jul 2014 | Not recommended | 66 individuals |
| enzalutamide Treatment of metastatic castration-resistant prostate cancer after failure of docetaxel-based chemotherapy. | Jul 2014 | Recommended with restriction | input received |
| abiraterone Initial and continuing treatment, in combination with prednisone or prednisolone, of a patient with metastatic advanced prostate cancer (castration resistant… | Jul 2012 | Not recommended | unclear |
| abiraterone Initial and continuing treatment, in combination with prednisone or prednisolone, of a patient with metastatic advanced prostate cancer (castration resistant… | Mar 2012 | Not recommended | unclear |
| abiraterone Initial and continuing treatment of metastatic castration-resistant prostate cancer in patients with disease progression following docetaxel treatment, in… | Mar 2012 | Not recommended | unclear |
| abiraterone for the treatment of metastatic advanced prostate cancer (castration resistant prostate cancer) in patients who have received prior chemotherapy containing a… | Nov 2012 | Recommended with restriction | no section in document |
| abiraterone Initial and continuing treatment of a patient with metastatic advanced prostate cancer (castration resistant prostate cancer) in patients whose disease… | Nov 2011 | Not recommended | no section in document |
| cabazitaxel treatment of hormone refractory metastatic carcinoma of the prostate in a patient previously treated with a docetaxel-containing regimen | Nov 2011 | Not recommended | unclear |
| cabazitaxel Treatment of hormone refractory metastatic carcinoma of the prostate in patients previously treated with a docetaxel-containing regimen. | Nov 2011 | Not recommended | unclear |
| docetaxel Treatment of androgen independent (hormone refractory) metastatic carcinoma of the prostate in a patient with a Karnofsky performance-status score of at least… | Jul 2007 | Recommended with restriction | no section in document |
| docetaxel Treatment of androgen independent (hormone refractory) metastatic carcinoma of the prostate in patients with a Karnofsky performance-status score of at least… | Jul 2007 | Recommended with restriction | no section in document |
| docetaxel treatment of androgen independent (hormone refractory) prostate cancer | Nov 2006 | Not recommended | no section in document |
| docetaxel Treatment of androgen independent (hormone refractory) prostate cancer, specifically metastatic androgen-independent prostate cancer. | Jul 2005 | Not recommended | no section in document |
Who spoke
Prostate Cancer Foundation · Rare Cancers Australia · Medical Oncology Group · Blue Mountains Prostate Cancer Support Group · Bega Valley Prostate Cancer Support Group · South Eastern Prostate Cancer Support Group · Prostate Cancer Support Group · Mens Cancer Support Group · Bayside Kingston Prostate Cancer Support Group · Cancer Support Group · Lakes Entrance Prostate Cancer Support Group · Grafton Prostate Cancer Support Group
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 12 of 21 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.